{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:16:48Z","timestamp":1778861808784,"version":"3.51.4"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:00:00Z","timestamp":1759017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology Case Reports"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.eucr.2025.103226","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T07:47:44Z","timestamp":1759304864000},"page":"103226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pembrolizumab-induced myasthenia gravis: A rare immune-related adverse event in a patient treated for bladder cancer"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5071-1025","authenticated-orcid":false,"given":"Stacy R.","family":"Bedore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle H.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"van der Eerden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan V.","family":"Town","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha K.","family":"Terris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.eucr.2025.103226_bib1","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.18632\/oncotarget.13895","article-title":"PD-1 and its ligands are important immune checkpoints in cancer","volume":"8","author":"Dong","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.eucr.2025.103226_bib2","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with Myositis\/Myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.eucr.2025.103226_bib3","article-title":"Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study","volume":"50","author":"Plomp","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"10.1016\/j.eucr.2025.103226_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaa181","article-title":"Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy","volume":"2","author":"Shelly","year":"2020","journal-title":"Brain Commun"},{"key":"10.1016\/j.eucr.2025.103226_bib5","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"Bmj"},{"issue":"3","key":"10.1016\/j.eucr.2025.103226_bib6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis","volume":"6","author":"Duan","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.eucr.2025.103226_bib7","doi-asserted-by":"crossref","first-page":"Itc17","DOI":"10.7326\/AITC202402200","article-title":"Immune-Related adverse events of immune checkpoint inhibitors","volume":"177","author":"Ramos-Casals","year":"2024","journal-title":"Ann Intern Med"},{"issue":"19","key":"10.1016\/j.eucr.2025.103226_bib8","doi-asserted-by":"crossref","first-page":"19491","DOI":"10.1002\/cam4.6559","article-title":"Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA adverse event reporting system","volume":"12","author":"Kong","year":"2023","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.eucr.2025.103226_bib9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/jcph.2187","article-title":"Characterization of immune checkpoint inhibitor-induced Myasthenia gravis using the US food and drug administration adverse event reporting system","volume":"63","author":"Niimura","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.eucr.2025.103226_bib10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis","volume":"11","author":"Huang","year":"2020","journal-title":"Front Neurol"},{"issue":"11","key":"10.1016\/j.eucr.2025.103226_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8111777","article-title":"Neurological immune related adverse events associated with Nivolumab, ipilimumab, and pembrolizumab therapy-review of the literature and future outlook","volume":"8","author":"M\u00f6hn","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.eucr.2025.103226_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1597259","article-title":"Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review","volume":"16","author":"S\u00e1nchez-Camacho","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.eucr.2025.103226_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1372861","article-title":"Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review","volume":"15","author":"Qin","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.eucr.2025.103226_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/5399073","article-title":"Immunotherapy-Induced overlap syndrome: myositis, myasthenia gravis, and Myocarditis-A case series","volume":"2024","author":"Aggarwal","year":"2024","journal-title":"Case Rep Med"},{"issue":"10","key":"10.1016\/j.eucr.2025.103226_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","article-title":"Neuromuscular complications of programmed cell Death-1 (PD-1) inhibitors","volume":"18","author":"Kao","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"5","key":"10.1016\/j.eucr.2025.103226_bib16","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"36","key":"10.1016\/j.eucr.2025.103226_bib17","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Urology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214442025002979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214442025002979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:57:09Z","timestamp":1778860629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214442025002979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":17,"alternative-id":["S2214442025002979"],"URL":"https:\/\/doi.org\/10.1016\/j.eucr.2025.103226","relation":{},"ISSN":["2214-4420"],"issn-type":[{"value":"2214-4420","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab-induced myasthenia gravis: A rare immune-related adverse event in a patient treated for bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eucr.2025.103226","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103226"}}